Medeon Biodesign (6499) — Capital Reinvestment Ratio
Latest as of March 2022:
0.68x
Medeon Biodesign (6499) has a Capital Reinvestment Ratio of 0.68x as of March 2022, meaning it reinvests 1% of its operating cash flow (NT$60.74 Million) in capital expenditures (NT$41.12 Million). See Medeon Biodesign free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.68x
Capex / Operating Cash Flow
Operating Cash Flow
NT$60.74 Million
TWD
Capital Expenditures
NT$41.12 Million
TWD
Data as of
Mar 2022
Most recent filing
Medeon Biodesign Capital Reinvestment Ratio (2018–2018)
This chart tracks Medeon Biodesign's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Medeon Biodesign (2018–2018)
Year-by-year Capital Reinvestment Ratio for Medeon Biodesign from 2018 to 2018. For live market cap and broader valuation context, see 6499 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 0.16x | NT$322.05 Million | NT$51.14 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow